Earn points on every order · Free shipping on orders over $159 · New products in stock
← Back to Compound Library
Growth Hormone Axis

IPAMORELIN

Cleanest of the GH-releasers. Gives you a natural GH pulse without dragging cortisol or prolactin up with it.

Research referenceCommunity compiled
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

Cleanest of the GH-releasers.

Gives you a natural GH pulse without dragging cortisol or prolactin up with it.

What It Does

Cleanest GHRP, selective GH secretagogue with minimal cortisol or prolactin elevation.

Selective GHS-R1a agonist without cortisol, prolactin, or appetite effects.

The preferred GHRP for CJC-1295 + Ipamorelin stacks.

Reconstitution

Vial SizeBAC Water / SolventConcentration
2 mg+ 0.4 mL5 mg/mL
5 mg+ 1 mL5 mg/mL
10 mg+ 2 mL5 mg/mL
Interactive tool

Reconstitution Calculator

Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.

Calculated concentration—Enter both values above.
Optional conversion

Enter a target amount you already have and select the syringe capacity.

Calculated draw—Enter concentration inputs and a target amount.

Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.

Protocol

PhaseFrequencyAmountNotes
Weeks 1–2Nightly 5×/week200 mcg6.0u Start low and assess how your body responds before increasing.
Weeks 3–12Nightly 5×/week300 mcg9.0u Standard effective dose for most users.
Off4 weeks–– Off period, let your pituitary and receptors recover before the next cycle.
Cycle & Timing

8–12 weeks on / 4–8 weeks off. Max: 16 weeks on / 4–8 weeks off. Cleanest GHRP receptor profile but cycling still preserves response.

Timing

Fasted pre-bed nightly (or fasted AM). No food 60–90 min before; no food 60 min after, cleanest GHRP profile.

Evidence Context

human PK established (Gobburu 1999, IV infusion); SubQ dosing extrapolated.

Population Considerations

Women make ~3× the GH of men yet have similar IGF-1, they’re less responsive, so often need a higher dose to move IGF-1. Oral estrogen blunts IGF-1 further (read it as running low); a skin patch/gel is more predictable. Men: Men convert GH to IGF-1 more efficiently and more often overshoot the age ceiling (a higher malignancy signal), aim mid-normal for age, don’t chase the Women make ~3× the GH of men yet have similar IGF-1, they’re less responsive, so often need a higher dose to move IGF-1. Oral estrogen blunts IGF-1 further (read it as running low); a skin patch/gel is more predictable. Men: Men convert GH to IGF-1 more efficiently and more often overshoot the age ceiling (a higher malignancy signal), aim mid-normal for age, don’t chase the top.

Handling & Stacking

Injection site
Abdomen preferred.
Storage
Freeze-dried: -4°F. Reconstituted: 36–46°F. Best used within 28 days, otherwise potency gradually fades over ~4–6 weeks (structure-based estimate, no published data).
Side effects
Mild water retention, brief tingling. Minimal cortisol/prolactin vs other GHRPs.
What to expect
  • Better sleep by 1–2 wks; mild tingling; body-composition change by 8–12 wks.
  • No appetite bump, the cleanest GHRP.
  • Supply math 2mg → 9 vials | 5mg → 4 vials | 10mg → 2 vials (12-wk @ 300 mcg × 5/wk)
Pairs well with
CJC-1295 (No DAC) (canonical pair, GH pulse synergy); Wolverine Blend (BPC-157 + TB-500) (recovery); Mod-GRF (additional GHRH pulse); MK-677 (extends GH window)
Avoid
Active malignancy. Severe insulin resistance
Approved drug
Somatropin (HGH) is approved for growth-hormone deficiency and tesamorelin (Egrifta) for HIV lipodystrophy. Secretagogues like this one are off-label.

Safety & Patient Education

Contraindications
Active malignancy of any kind (GH/IGF-1 can promote tumor growth) Severe diabetic retinopathy Acute critical illness (per somatropin label, applies to GH-axis stimulators) Pregnancy and lactation
Warnings
Insulin resistance and worsening glycemic control with sustained use Fluid retention, peripheral edema Carpal tunnel syndrome with extended use Joint and muscle pain IGF-1 elevation: theoretical malignancy promotion if dosed beyond physiological IGF-1 ranges Cleanest GHRP profile (minimal cortisol/prolactin); class warnings still apply but at lower magnitude
Drug interactions
Glucocorticoids: blunt GH response, minimize or time away from injection Insulin / antidiabetics: GH worsens insulin resistance, expect dose adjustments + tighter monitoring Levothyroxine: GH lowers free T4, recheck TSH/fT4 quarterly Oral estrogens: blunt GH-stimulated IGF-1, transdermal doesn’t
Labs
  • IGF-1 (baseline / mid / end; target ULN for age), Lipid panel (Week 0/12) Fasting glucose and HbA1c at baseline and end of cycle Mammogram and prostate screening per age-appropriate guidelines before starting Out of range?
  • IGF-1 above your age range = too much growth signal → drop the dose.
Stop criteria
Fasting glucose rises >20 mg/dL above baseline IGF-1 rises above the upper limit of normal for age New persistent joint pain or carpal tunnel symptoms New skin changes or moles enlarging Vision changes
Patient education
GH-axis stimulation is not appropriate during active malignancy or for fertility Most GH pulses occur during deep sleep, dose pre-bed unless instructed otherwise Food within 90 min of injection blunts GH response (carbs/fats most), fasted is standard Report new lumps, persistent headaches, or vision changes immediately
References
researchdosing · peptidedosages · PubMed · thepeptidereport · peptides.id · Span 2000 · Weissberger 1991